Moderna jumped 6.5% in one session, a tidy pop for a name that is still shrinking fast and digging out of factory bills.
On one side you have a market value of $22.5B and an EV/sales multiple of 10.6x. On the other you have a company whose revenue has fallen from $18.5B in 2021 to $1.9B in 2025 and whose operating margin is a negative 158.1%.
Management’s filings repeatedly point to the same mechanical drag: capacity built for a different demand era, and the costs that linger while the business rebalances.
"Excluding these expenses, cost of sales and cost of sales as a percentage of net product sales and stand-ready manufacturing revenue for the six months ended June 30, 2026 decreased by 59% and 65 percentage points, respectively, compared to the same period in 2025, primarily due to lower unutilized manufacturing capacity costs and losses on firm purchase commitments, partially offset by higher sales volume." [Moderna / 10-Q 2026-07-31]
That sentence does a lot of heavy lifting. It says costs fell once you strip out capacity-related cash burn and write-offs, which is literally management separating ongoing product economics from the cleanup bill for excess factories and firm purchase commitments.
Filings also call out the scale of pre-existing arrangements that can keep costs on the books even as sales fall.
"At December 31, 2025, we had cancelable open purchase orders of approximately $ 1.8 billion, reflecting amounts associated with our significant vendor arrangements, under such agreements for our clinical operations and support and contract manufacturing." [Moderna / 10-K 2026-02-20]
That $1.8B headline is not revenue; it is future commitments that can create losses, write-downs, or late exits depending on how contracts and inventory unwind.
On R&D, management says the deck is thinning too: several late-stage programs are winding down and they expect "a modest reduction in research and development expenses in 2026 compared to 2025," driven by program wind-downs and cost discipline. That reduces near-term spend, but it also signals the pipeline’s cadence is shifting.
"We anticipate a modest reduction in research and development expenses in 2026 compared to 2025, primarily driven by the wind-down of several late-stage programs, continued disciplined cost management, and a focused approach to pipeline execution." [Moderna / 10-Q 2026-07-31]
The arithmetic the company itself lays out explains why models diverge: some investors who believe the business re-accelerates and the market assigns a big multiple treat Moderna as a growth play, while others who view the remaining revenue base and capacity cleanup as persistent drags take a more skeptical view of the valuation. The company’s own scenario framing shows that the gap between a bullish and bearish outcome is enormous, and most of that gap is driven by what multiple the market will apply to whatever revenue path plays out.
That is the tension investors are trading: a high valuation priced for a return to growth, versus repeated, explicit filing notes about excess capacity, purchase commitments, inventory write-downs and shrinking revenue. The filings do not pick a side; they just list the bills that still have to be reconciled.
Figures and quotes are drawn from Moderna’s public filings (10-Q 2026-07-31; 10-K 2026-02-20).